Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $14.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $15.00 | Buy | B. Riley Securities |
| 1/19/2024 | $14.00 | Buy | Jefferies |
| 2/24/2023 | $15.00 | Overweight | Piper Sandler |
| 2/7/2023 | $20.00 | Buy | Chardan Capital Markets |
H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00
B. Riley Securities initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00
Jefferies initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00
SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies London Healthcare Conference being held in London, UK from November 19-21, 2024. Details of the presentation are shown below. Format: Fireside Chat Date: Tuesday, November 19, 2024 Time: 1:00 PM GMT Webcast: https://wsw.com/webcast/jeff315/obio/1840692 A replay of the webcast will be available on the Events section of the Orchest
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update. "Our work in hypertension and coronary artery disease aligns with a renaissance occurring in cardiac pacing and balloon angioplasty, applying new innovations to enhance these foundational device-based interventions and create more potent therapeutic solutions. At our inaugural R&D day in June, we were excited to share our insights into this renais
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic's President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years
144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc
Chardan Capital analyst Keay Nakae reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $620.00 thousand which missed the analyst consensus estimate of $940.00 thousand by 34.04 percent. This is a 46.74 percent decrease over sales of $1.16 million the same period last year.
Gainers Twist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out today. Jaguar Health (NASDAQ:JAGX) shares increased by 13.91% to $0.33. The company's market cap stands at $95.9 million. Tandem Diabetes Care (NASDAQ:TNDM) stock moved upwards by 12.25% to $41.04. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out today. Indaptus Therapeutics (NASDAQ:INDP) stock moved upwards by 11.29% to $2.26. The company's market cap stands at $19.2 million. Ardelyx (NASDAQ:ARDX) shares rose 11.02% to $7.54. Th
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic's President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years
David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott VascularMr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward shar
FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi